Abstract
Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Volume: 8 Issue: 4
Author(s): Sebastian Di Cesare, Daniel Abourbih, Rubens N. Belfort, Luca A. Petruccelli and Miguel N. Burnier Jr.
Affiliation:
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Abstract: Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Export Options
About this article
Cite this article as:
Di Cesare Sebastian, Abourbih Daniel, Belfort N. Rubens, Petruccelli A. Luca and Burnier Jr. N. Miguel, Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (4) . https://dx.doi.org/10.2174/187152309789839046
DOI https://dx.doi.org/10.2174/187152309789839046 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials The Antinflammatory Effect of Alpha-MSH in Skin: A Promise for New Treatment Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Imatinib Mesylate: An Innovation in Treatment of Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design NKT Cells: A Regulator in Both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Nano-formulations for Diagnostics and Therapeutics of Foot-and-Mouth Disease in Animals
Nanoscience & Nanotechnology-Asia